Yearly Life Sciences Reports of the Netherlands
The life sciences industry remains very strong in the Netherlands. It currently consist of about 1000 companies, half of which belong to the biotechnology sector. The majority of products in companies’ pipelines are in the area of oncology, followed by the products indicated for infectious diseases. In 2017, there were 12 major financing rounds in … Continue reading Dutch Life Sciences Trend Analysis 2018
Our annual trend report for the Dutch life sciences market shows that the country remains an important centre of the industry. There were 14 major financing rounds in the biotech sector in 2016 for the total amount of 71 million USD. However, the number of newly founded companies was much lower in 2016 than in … Continue reading Dutch Life Sciences Trend Analysis 2017
While the first semester of 2015 was a quiet period, the second half of last year saw private Dutch biotech companies raise over USD 115m worth of funding in six rounds. Indeed it proved to be the largest financing period since the first semester of 2012. Dutch LS Trend Analysis 2016 Looking for your … Continue reading Dutch Life Sciences Trend Analysis 2016
3 Dutch companies, ProQR, UniQure and arGEN-X went public and raised approximately USD 272.5M combined. Nonetheless, the Biotech industry in the Netherlands has faced a drop in financing value of more than 50% whilst the number of rounds has decreased by 21%. The number of Biotech companies in the Netherlands has however increased significantly, from … Continue reading Dutch Life Sciences Trend Analysis 2015
With a strong finish in the second half of 2013, the Dutch, private biotechnology companies closed the year having amassed a total of USD 158m in venture financing. The strongest therapeutic areas, as represented by the biotech product pipeline (Therapeutics and Diagnostics), are those of Oncology (53 products in development), Infectious Diseases (36 products) and … Continue reading Dutch Life Sciences Trend Analysis 2014
